Home › Stock analysis › BMY
Bristol Myers Squibb (BMY) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
BMY rises 2.2% to $60.57. Closed at $60.57, +2.18% vs the prior close of $59.28. Day range $60.39–$62.25, opened at $60.67.
Last close$60.57+2.18%
Day range60.39–62.25
Open60.67
Volume13.75M
52-week range42.52–68.64
Avg volume (20d)14.83M
BMY daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — BMY rises 2.2% to $60.57
- Closed at $60.57, +2.18% vs the prior close of $59.28. Day range $60.39–$62.25, opened at $60.67.
- Volume was 13.75M shares, 1.3x its 50-day average of 10.89M.
- Price is -4.8% vs its 50-day average ($63.59) and +1.6% vs its 200-day average ($59.61).
- 52-week range $42.52–$68.64; today's close sits at 69% of that range, 11.8% below the 52-week high.
Oct 14, 2026 — BMY jumps 4.6% to $59.28
- Closed at $59.28, +4.61% vs the prior close of $56.67. Day range $56.58–$59.39, opened at $56.81.
- Volume was 14.05M shares, 1.3x its 50-day average of 11.07M.
- Price is -6.9% vs its 50-day average ($63.66) and -0.5% vs its 200-day average ($59.58).
- 52-week range $42.52–$68.64; today's close sits at 64% of that range, 13.6% below the 52-week high.
Oct 13, 2026 — BMY dips 1.6% to $56.67, a 3-month low, 4 down days in a row
- Closed at $56.67, -1.58% vs the prior close of $57.58. Day range $56.15–$58.02, opened at $57.78.
- Volume was 16.96M shares, 1.5x its 50-day average of 11.40M.
- Price is -11.2% vs its 50-day average ($63.79) and -4.8% vs its 200-day average ($59.56).
- 52-week range $42.52–$68.64; today's close sits at 54% of that range, 17.4% below the 52-week high.
- That makes 4 straight losses.
Oct 12, 2026 — BMY dips 2.6% to $57.58, a 1-month low on 2.0x normal volume
- Closed at $57.58, -2.60% vs the prior close of $59.12. Day range $56.72–$60.68, opened at $60.11.
- Volume was 22.56M shares, 2.0x its 50-day average of 11.24M — unusually heavy trading.
- Price is -10.0% vs its 50-day average ($63.96) and -3.3% vs its 200-day average ($59.55).
- 52-week range $42.52–$68.64; today's close sits at 58% of that range, 16.1% below the 52-week high.
- That makes 3 straight losses.
Oct 9, 2026 — BMY dips 0.8% to $59.12
- Closed at $59.12, -0.77% vs the prior close of $59.58. Day range $58.74–$59.79, opened at $58.88.
- Volume was 9.25M shares, 0.8x its 50-day average of 11.41M.
- Price is -7.8% vs its 50-day average ($64.12) and -0.7% vs its 200-day average ($59.53).
- 52-week range $42.52–$68.64; today's close sits at 64% of that range, 13.9% below the 52-week high.
Oct 8, 2026 — BMY ends flat (-0.2%) to $59.58
- Closed at $59.58, -0.20% vs the prior close of $59.70. Day range $58.73–$59.94, opened at $59.10.
- Volume was 13.07M shares, 1.2x its 50-day average of 11.36M.
- Price is -7.2% vs its 50-day average ($64.23) and +0.1% vs its 200-day average ($59.51).
- 52-week range $42.52–$68.64; today's close sits at 65% of that range, 13.2% below the 52-week high.
Oct 7, 2026 — BMY ends flat (+0.2%) to $59.70
- Closed at $59.70, +0.18% vs the prior close of $59.59. Day range $59.01–$60.10, opened at $59.45.
- Volume was 11.09M shares, 1.0x its 50-day average of 11.44M.
- Price is -7.2% vs its 50-day average ($64.30) and +0.4% vs its 200-day average ($59.48).
- 52-week range $42.52–$68.64; today's close sits at 66% of that range, 13.0% below the 52-week high.
Oct 6, 2026 — BMY rises 1.3% to $59.59
- Closed at $59.59, +1.33% vs the prior close of $58.81. Day range $58.64–$59.60, opened at $58.94.
- Volume was 9.89M shares, 0.9x its 50-day average of 11.45M.
- Price is -7.4% vs its 50-day average ($64.38) and +0.2% vs its 200-day average ($59.45).
- 52-week range $42.52–$68.64; today's close sits at 65% of that range, 13.2% below the 52-week high.
Oct 5, 2026 — BMY slides 3.8% to $58.81, a 1-month low, 5 down days in a row
- Closed at $58.81, -3.83% vs the prior close of $61.15. Day range $58.33–$60.15, opened at $59.89.
- Volume was 19.24M shares, 1.7x its 50-day average of 11.31M.
- Price is -8.7% vs its 50-day average ($64.44) and -1.0% vs its 200-day average ($59.42).
- 52-week range $42.52–$68.64; today's close sits at 62% of that range, 14.3% below the 52-week high.
- That makes 5 straight losses.
Oct 2, 2026 — BMY dips 0.5% to $61.15, 4 down days in a row
- Closed at $61.15, -0.50% vs the prior close of $61.46. Day range $60.24–$61.24, opened at $60.66.
- Volume was 9.93M shares, 0.9x its 50-day average of 11.26M.
- Price is -5.2% vs its 50-day average ($64.51) and +3.0% vs its 200-day average ($59.40).
- 52-week range $42.52–$68.64; today's close sits at 71% of that range, 10.9% below the 52-week high.
- That makes 4 straight losses.
Things to know before you trade BMY
- Last results release: Jul 30, 2026 (8-K Item 2.02). Previous ones: Apr 30, 2026, Feb 5, 2026, Oct 30, 2025. Based on that rhythm, the next report is likely around Oct 29, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.47% (largest 4.6%).
- Liquidity: about 14.83M shares (≈$898.32M) trade per day on average.
- 52-week position: $60.57 vs a range of $42.52–$68.64 (69% of the range).
- Dividends: last ex-dividend date Oct 2, 2026 ($0.63/share); 4 payments in the past 12 months.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 4 sales; latest: Cristian Massacesi sold 6,249 shares on Sep 9, 2026.
- Latest filings: 10-Q Jul 30, 2026; 8-K Jul 30, 2026; 8-K May 8, 2026.
- Share count: 2.04B shares outstanding (Jul 22, 2026), +0.4% vs a year earlier.
- Listing: NYSE · industry: Pharmaceutical Preparations.
BMY market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 60.67 | 62.25 | 60.39 | 60.57 | 13.75M |
| Oct 14, 2026 | 56.81 | 59.39 | 56.58 | 59.28 | 14.05M |
| Oct 13, 2026 | 57.78 | 58.02 | 56.15 | 56.67 | 16.96M |
| Oct 12, 2026 | 60.11 | 60.68 | 56.72 | 57.58 | 22.56M |
| Oct 9, 2026 | 58.88 | 59.79 | 58.74 | 59.12 | 9.25M |
| Oct 8, 2026 | 59.10 | 59.94 | 58.73 | 59.58 | 13.07M |
| Oct 7, 2026 | 59.45 | 60.10 | 59.01 | 59.70 | 11.09M |
| Oct 6, 2026 | 58.94 | 59.60 | 58.64 | 59.59 | 9.89M |
| Oct 5, 2026 | 59.89 | 60.15 | 58.33 | 58.81 | 19.24M |
| Oct 2, 2026 | 60.66 | 61.24 | 60.24 | 61.15 | 9.93M |
| Oct 1, 2026 | 62.20 | 62.61 | 61.25 | 61.46 | 10.77M |
| Sep 30, 2026 | 63.28 | 64.13 | 62.40 | 62.40 | 15.87M |
| Sep 29, 2026 | 63.58 | 63.89 | 61.95 | 62.86 | 15.84M |
| Sep 28, 2026 | 62.77 | 63.93 | 62.30 | 63.88 | 14.02M |
| Sep 25, 2026 | 61.75 | 62.91 | 61.40 | 62.86 | 10.67M |
| Sep 24, 2026 | 61.40 | 61.59 | 60.60 | 61.50 | 14.90M |
| Sep 23, 2026 | 62.31 | 62.65 | 61.08 | 61.15 | 15.84M |
| Sep 22, 2026 | 62.73 | 63.08 | 62.03 | 62.25 | 15.24M |
| Sep 21, 2026 | 63.09 | 63.40 | 62.62 | 62.62 | 6.84M |
| Sep 18, 2026 | 62.71 | 63.07 | 62.19 | 63.06 | 36.85M |
About Bristol Myers Squibb
Bristol Myers Squibb (BMY) is listed on the NYSE and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in PRINCETON, NJ. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 14272.
BMY board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Peter J Arduini | Director | Jul 2, 2026 |
| Christopher S. Boerner | Chief Executive Officer | Mar 12, 2026 |
| Deepak Bhatt | Director | Feb 3, 2026 |
| Julia A Haller | Director | Jun 16, 2026 |
| Medina Manuel Hidalgo | Director | Feb 3, 2026 |
| Michael R. Mcmullen | Director | Jul 2, 2026 |
| Paula A Price | Director | Feb 3, 2026 |
| Derica W Rice | Director | Jul 2, 2026 |
| Theodore R. Ii Samuels | Director | Jul 2, 2026 |
| Karen H Vousden | Director | Feb 3, 2026 |
| Phyllis R Yale | Director | Jul 2, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Christopher S. Boerner | Chief Executive Officer | Mar 12, 2026 |
| David V Elkins | EVP, Chief Financial Officer | Apr 2, 2026 |
| Cari Gallman | EVP, General Counsel | Aug 4, 2026 |
| Benjamin Hickey | President, RayzeBio Org. | Mar 12, 2026 |
| Lynelle Hoch | President, Cell Therapy Org. | Mar 12, 2026 |
| Phil M Holzer | SVP and Controller | Aug 26, 2026 |
| Adam Lenkowsky | EVP, Chief Commercial Officer | May 5, 2026 |
| Cristian Massacesi | EVP,Chief Med Offr,Head of Dev | Sep 10, 2026 |
| Gregory Scott Meyers | EVP, Chief Digital & Tech Off. | Mar 12, 2026 |
| Robert M Plenge | EVP, Chief Research Officer | Mar 12, 2026 |
| Ahn Amanda Poole | EVP, Chief People Officer | Mar 12, 2026 |
| Karin Shanahan | EVP, Chief Supply Chain & Ops | Apr 2, 2026 |
| Hiroshi Chris Shibutani | EVP, Chief Strategy Officer | Mar 12, 2026 |
| Bartie Wendy Short | EVP, Corporate Affairs | Sep 3, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 9, 2026 | Cristian Massacesi | Sale | 6,249 | $64.57 |
| Aug 25, 2026 | Phil M Holzer | Sale | 500 | $67.50 |
| Apr 1, 2026 | David V Elkins | Sale | 25,519 | $61.60 |
| Apr 1, 2026 | David V Elkins | Sale | 4,481 | $62.05 |
BMY financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $48.19B | $7.05B | 3.46 | $14.16B |
| Dec 31, 2024 | $48.30B | $-8.95B | -4.41 | $15.19B |
| Dec 31, 2023 | $45.01B | $8.03B | 3.86 | $13.86B |
| Dec 31, 2022 | $46.16B | $6.33B | 2.95 | $13.07B |
| Dec 31, 2021 | $46.38B | $6.99B | 3.12 | $16.21B |
Latest balance sheet: total assets $87.63B, total liabilities $65.31B, cash $8.72B (as of Jun 30, 2026).
BMY earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Jul 30, 2026 | 8-K Item 2.02 (results) | $64.86 |
| Apr 30, 2026 | 8-K Item 2.02 (results) | $60.59 |
| Feb 5, 2026 | 8-K Item 2.02 (results) | $59.52 |
| Oct 30, 2025 | 8-K Item 2.02 (results) | $45.62 |
| Jul 31, 2025 | 8-K Item 2.02 (results) | $43.31 |
| Apr 24, 2025 | 8-K Item 2.02 (results) | $48.69 |
| Feb 6, 2025 | 8-K Item 2.02 (results) | $57.42 |
| Oct 31, 2024 | 8-K Item 2.02 (results) | $55.77 |
| Jul 26, 2024 | 8-K Item 2.02 (results) | — |
| Apr 25, 2024 | 8-K Item 2.02 (results) | — |
| Feb 2, 2024 | 8-K Item 2.02 (results) | — |
| Oct 26, 2023 | 8-K Item 2.02 (results) | — |
More on BMY
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.